Drug intelligence / Profile preview

GSB-D248

Development stage: Preclinical
Lead developer: Greenstone Biosciences
Administration: Oral

Overview

GSB-D248 is an investigational therapeutic candidate being developed by Greenstone Bio for the treatment of inflammatory diseases. Currently in the IND-enabling phase of development, the drug was identified using Greenstone's proprietary discovery platform, which leverages patient-derived induced pluripotent stem cells (iPSCs) to model human disease and screen for effective compounds. This 'Clinical Trial in a Dish' approach is designed to enhance the translational success of preclinical assets by utilizing human-relevant models early in the discovery process. While specific details regarding the molecular target, chemical modality, and mechanism of action for GSB-D248 have not been publicly disclosed, it represents a lead program in the company's immunology pipeline.

Beyond the preview

Go deeper on GSB-D248.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSB-D248.

Explore the full profile